{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=BRCA+Mutated&page=2",
    "query": {
      "condition": "BRCA Mutated",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=BRCA+Mutated&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:47:24.613Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06177171",
      "title": "Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "BRCA1 Mutation",
        "BRCA2 Mutation",
        "BRCA Mutation",
        "PALB2 Gene Mutation",
        "Checkpoint Kinase 2 Gene Mutation",
        "ATM Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "ASTX727",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pamela Munster",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2024-02-07",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-05-22T09:47:24.613Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06177171"
    },
    {
      "nct_id": "NCT01670500",
      "title": "Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2012-10",
      "completion_date": "2025-02-02",
      "has_results": true,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-05-22T09:47:24.613Z",
      "location_count": 15,
      "location_summary": "Aurora, Colorado • Derby, Connecticut • Guilford, Connecticut + 9 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Derby",
          "state": "Connecticut"
        },
        {
          "city": "Guilford",
          "state": "Connecticut"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01670500"
    },
    {
      "nct_id": "NCT02571725",
      "title": "PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New Mexico Cancer Research Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2016-02-23",
      "completion_date": "2027-07-15",
      "has_results": false,
      "last_update_posted_date": "2025-05-23",
      "last_synced_at": "2026-05-22T09:47:24.613Z",
      "location_count": 5,
      "location_summary": "Tampa, Florida • Albuquerque, New Mexico • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02571725"
    },
    {
      "nct_id": "NCT01034891",
      "title": "Women At Risk: The High Risk Breast Cancer Program",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "New York Presbyterian Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 2000,
      "start_date": "1991-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-12-18",
      "last_synced_at": "2026-05-22T09:47:24.613Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01034891"
    },
    {
      "nct_id": "NCT06436248",
      "title": "Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ovarian Cancer",
        "BRCA Mutation"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "25 Years and older · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2024-07-01",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2025-10-22",
      "last_synced_at": "2026-05-22T09:47:24.613Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06436248"
    },
    {
      "nct_id": "NCT01907789",
      "title": "Prophylactic Salpingectomy With Delayed Oophorectomy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "Ovarian Cancer Screening",
          "type": "OTHER"
        },
        {
          "name": "Prophylactic Salpingectomy with Delayed Oophorectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Risk-Reducing Salpingo-Oophorectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Transvaginal Ultrasound",
          "type": "PROCEDURE"
        },
        {
          "name": "Phone Call",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "47 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 47 Years · Female only"
      },
      "enrollment_count": 80,
      "start_date": "2013-08-26",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-05-22T09:47:24.613Z",
      "location_count": 2,
      "location_summary": "Evanston, Illinois • Houston, Texas",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01907789"
    },
    {
      "nct_id": "NCT02000622",
      "title": "Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer Metastatic",
        "BRCA 1 Gene Mutation",
        "BRCA 2 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Physician's choice chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 302,
      "start_date": "2014-03-27",
      "completion_date": "2025-12-23",
      "has_results": true,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-05-22T09:47:24.613Z",
      "location_count": 42,
      "location_summary": "San Diego, California • Santa Rosa, California • Whittier, California + 35 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02000622"
    },
    {
      "nct_id": "NCT01078662",
      "title": "Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian",
        "Breast",
        "Prostate",
        "Pancreatic",
        "Advanced Tumours"
      ],
      "interventions": [
        {
          "name": "olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 298,
      "start_date": "2010-02-21",
      "completion_date": "2024-08-12",
      "has_results": true,
      "last_update_posted_date": "2025-08-13",
      "last_synced_at": "2026-05-22T09:47:24.613Z",
      "location_count": 2,
      "location_summary": "West Hollywood, California • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01078662"
    },
    {
      "nct_id": "NCT00080756",
      "title": "Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "brca1 Mutation Carrier",
        "brca2 Mutation Carrier",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "therapeutic estradiol",
          "type": "BIOLOGICAL"
        },
        {
          "name": "deslorelin",
          "type": "DRUG"
        },
        {
          "name": "therapeutic testosterone",
          "type": "DRUG"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "active surveillance",
          "type": "OTHER"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "48 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 48 Years · Female only"
      },
      "enrollment_count": 11,
      "start_date": "2004-03-11",
      "completion_date": "2024-10-15",
      "has_results": false,
      "last_update_posted_date": "2024-08-28",
      "last_synced_at": "2026-05-22T09:47:24.613Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00080756"
    },
    {
      "nct_id": "NCT01482715",
      "title": "A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer",
        "Advanced Solid Tumor With Evidence of Germline or Somatic BRCA"
      ],
      "interventions": [
        {
          "name": "Rucaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "pharmaand GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 136,
      "start_date": "2011-11",
      "completion_date": "2019-05",
      "has_results": true,
      "last_update_posted_date": "2023-06-09",
      "last_synced_at": "2026-05-22T09:47:24.613Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01482715"
    }
  ]
}